By Colin Kellaher
Keros Therapeutics shares rose sharply in premarket trading Thursday after the clinical-stage biopharmaceutical company said it is reviewing alternatives aimed at maximizing shareholder value, including a possible sale.
Shares of the Lexington, Mass., company, which closed Wednesday at $10.33, were recently up more than 18% to $12.23 in premarket trading.
Keros, which had a market capitalization of around $396 million based on Wednesday's closing price, said it will look at a range of options, including a sale or other business combination, continued investment in its pipeline, and the return of excess capital to shareholders.
The company said it hasn't set a deadline or timetable for completion of the review, adding that it has adopted a limited-duration shareholder rights plan with a 10% trigger to protect the integrity of the process.
Keros said the rights plan, also known as a "poison pill," is in response to the significant and rapid accumulations of its stock by a number of investors that it said have indicated a desire to influence the control of the company, including an individual investor that said it holds an 11.2% stake.
Poison pills are anti-takeover measures that flood the market with new shares, making it more expensive for suitors to acquire a controlling stake in a company.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
April 10, 2025 06:40 ET (10:40 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.